1. ScholarBank@NUS

Ross Andrew Soo

rp03556

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Ross Andrew Soo
(not current staff)
Variants
Ross, S.
Soo, R.
Soo, R.-A.
Soo, R.A.
Soo, Ross
 
Main Affiliation
 
Faculty
 
Email
csiras@nus.edu.sg
 

Publications

Refined By:
Policy:  Open
Subject:  Oncology

Results 1-10 of 10 (Search time: 0.007 seconds).

Issue DateTitleAuthor(s)
11-Mar-2022A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesHo, Jingshan ; Heong, Valerie; Yong, Wei Peng ; Soo, Ross ; Chee, Cheng Ean ; Wong, Andrea ; Sundar, Raghav; Thian, Yee Liang ; Gopinathan, Anil ; Pang, Mei Yan; Koe, Priscillia; Jeraj, Santhiay Nathan; Soe, Phyu Pyar; Soe, Mu Yar; Tang, Tiffany ; Ng, Matthew CH; Tai, David WM ; Tan, Tira JY ; Xu, Hongmei; Chang, Hua; Landesman, Yosef; Shah, Jatin ; Shacham, Sharon; Lee, Soo Chin ; Tan, Daniel SW ; Goh, Boon Cher ; Tan, David SP 
215-Apr-2023A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesChee, Cheng E ; Ooi, Melissa ; Lee, Soo-Chin ; Sundar, Raghav ; Heong, Valerie; Yong, Wei-Peng ; Ng, Chin Hin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Tan, Joshua TC; Yang, Song; Thura, Min; Al-Aidaroos, Abdul Qader; Chng, Wee Joo ; Zeng, Qi ; Goh, Boon-Cher 
316-Feb-2023Clinical outcome and prognostic factors for Asian patients in Phase I clinical trialsLoh, Jerold; Wu, Jiaxuan; Chieng, Jenny; Chan, Aurora; Yong, Wei-Peng ; Sundar, Raghav ; Lee, Soo-Chin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Goh, Boon-Cher ; Tai, Bee-Choo ; Chee, Cheng E 
4Sep-2022Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLCHuang, Y; Zhao, JJ; Soon, YY; Kee, A; Tay, SH; Aminkeng, F ; Ang, Y; Wong, A; Goh, BC; Soo, R 
512-May-2023Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerHuang, Yiqing; Zhao, Joseph J; Soon, Yu Yang; Kee, Adrian; Tay, Sen Hee; Aminkeng, Folefac ; Ang, Yvonne; Wong, Alvin SC; Bharwani, Lavina D; Goh, Boon Cher; Soo, Ross A 
61-Jul-2015MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell CarcinomaKong, Li Ren ; Chua, Kian Ngiap ; Sim, Wen Jing ; Ng, Hsien Chun ; Bi, Chonglei; Ho, Jingshan ; Nga, Min En ; Pang, Yin Huei ; Ong, Weijie Richard; Soo, Ross Andrew ; Huynh, The Hung ; Chng, Wee Joo ; Thiery, Jean-Paul ; Goh, Boon Cher 
71-Jun-2022Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patientsHuang, Yiqing; Aminkeng, Folefac ; Wong, Alvin SC; Tay, Sen Hee ; Zhao, Joseph J; Ang, Yvonne; Soo, Ross A ; Goh, Boon Cher 
823-Feb-2022Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin +/- Trastuzumab in Advanced Solid TumorsLee, Matilda Xinwei; Wong, Andrea LA ; Ow, Samuel; Sundar, Raghav ; Tan, David SP ; Soo, Ross A ; Chee, Cheng Ean ; Lim, Joline SJ ; Yong, Wei Peng ; Lim, Siew Eng; Goh, Boon Cher ; Wang, Lingzhi ; Lee, Soo Chin 
91-Nov-2017Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)Nokihara, H; Lu, S; Mok, TSK; Nakagawa, K; Yamamoto, N; Shi, YK; Zhang, L; Soo, RA ; Yang, JC; Sugawara, S; Nishio, M; Takahashi, T; Goto, K; Chang, J; Maemondo, M; Ichinose, Y; Cheng, Y; Lim, WT ; Morita, S; Tamura, T
1030-Sep-2022Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancerHuang, Yiqing; Zhao, Joseph J; Soon, Yu Yang ; Wong, Alvin; Aminkeng, Folefac ; Ang, Yvonne; Asokumaran, Yugarajah; Low, Jia Li; Lee, Matilda; Choo, Joan RE; Chan, Gloria; Kee, Adrian ; Tay, Sen Hee ; Goh, Boon Cher ; Soo, Ross A